ADAMTS-18 is a member of the A Disintegrin and Metalloproteinase with Thrombospondin Motifs (ADAMTS) family of enzymes, which play critical roles in extracellular matrix (ECM) remodeling, cell adhesion, and a variety of other biological processes. These enzymes are known for their proteolytic activity on various substrates, including proteoglycans and glycoproteins. The modulation of ADAMTS-18 and other ADAMTS proteins occurs through an intricate interplay of signaling pathways, including but not limited to TGF-β, Wnt, and various cytokine-mediated pathways. These pathways can affect both the expression and activity of ADAMTS-18, thereby influencing its role in ECM turnover and cellular function. Additionally, the substrate specificity of ADAMTS-18 is guided by its thrombospondin motifs and its metalloproteinase activity, which can be modulated by endogenous inhibitors or by chemical activators.
Specific small molecules targeting ADAMTS-18 are compounds that either directly enhance the enzyme's proteolytic activity or indirectly promote its expression or function. Indirect activators could function through a variety of mechanisms, such as epigenetic modulation, affecting substrate availability, or inhibiting opposing pathways. For instance, molecules inhibiting pathways that downregulate ADAMTS-18 could serve as indirect activators. Similarly, compounds that affect the stability, folding, or post-translational modification of ADAMTS-18 could potentially serve as direct activators. Understanding the intricacies of ADAMTS-18 activation involves a multi-faceted approach, taking into consideration both direct and indirect modulation, and is an evolving field within cellular and molecular biology.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
DNA Methyltransferase Inhibitors could affect the methylation status of the ADAMTS-18 gene, potentially increasing its expression. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
NF-κB Inhibitors could potentially upregulate ADAMTS-18 by suppressing NF-κB signaling, if NF-κB acts as a suppressor. | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $36.00 $117.00 $525.00 | 26 | |
Wnt Pathway Inhibitors may influence ADAMTS-18 by affecting Wnt signaling, which is known to be involved in ECM remodeling. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
PKC Inhibitors could influence various signaling pathways that may indirectly activate ADAMTS-18. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
JAK/STAT Inhibitors may affect the cytokine signaling that influences ADAMTS-18 expression or activity. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
MEK Inhibitors could affect MAPK pathways that influence ADAMTS-18. | ||||||
Cobalt(II) chloride | 7646-79-9 | sc-252623 sc-252623A | 5 g 100 g | $64.00 $176.00 | 7 | |
HIF-1α Stabilizers could potentially influence the hypoxia-related activation or expression of ADAMTS-18. | ||||||